ClinicalTrials.gg
Status unknownNCT05549115Updated Dec 12, 2023

Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection

An interventional study of clarithromycin-sensitive(first-line) and clarithromycin-resistant(first-line) in Helicobacter Pylori Infection, sponsored by Liaocheng People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-12.

Sponsored by Liaocheng People's Hospital · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main objective of this trial is to assess whether a sequential therapy strategy based on molecular antibiotic susceptibility testing (including clarithromycin and fluoroquinolone) for H. pylori infection will improve the eradication rate compared to an empirical therapy.

Read the detailed description

This trial is designed as a prospective, randomised, open-label, active-controlled and single-centre study. For empirical therapy group(control group), Bismuth quadruple therapy will be an empirical first-line therapy, and high dose dual (proton-pump inhibitor + amoxicillin) treatment will be for rescue therapy if the first-line empirical treat failure. For the susceptibility-guided sequential therapy group, regimens were selected based on H. pylori susceptibility to clarithromycin and levofloxacin. The primary outcome is the first-line eradication rate in both groups, and the overall (including first- and rescue therapies) H. pylori eradication rates in both groups is one of the secondary outcomes. The eradication rates of H. pylori will be analysed by intention-to-treat analysis, modified intention-to-treat analysis and per-protocol analysis.

02

Conditions studied

  • Helicobacter Pylori Infection

Keywords

  • Helicobacter pylori
  • Drug Resistance, Microbial
  • Microbial Sensitivity Tests
03

In context

Lead sponsor

Liaocheng People's Hospital is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • H. pylori infection was determined using at least one of the following tests: 13C/14C-urea breath test (UBT), stool H. pylori antigen test, rapid urease test, and histological analysis within 4 weeks.
  • Patients were naïve to H. pylori treatment.

Exclusion criteria

Exclusion Criteria:

  • Allergy to any drug administered.
  • Pregnancy and lactation.
  • Major systemic diseases, such as severe cardiopulmonary or liver dysfunction.
  • Complicated with active peptic ulcer disease, gastric cancer, or prior gastrectomy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    clarithromycin-sensitive(first-line)

    If H. pylori is sensitive to clarithromycin, we will administer clarithromycin triple therapy-esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily)-for 14 days

    Drug: clarithromycin-sensitive(first-line)

  • Experimental
    clarithromycin-resistant(first-line)

    If H. pylori is clarithromycin resistance, we selected the High-dose dual therapy (HDDT) regimen as first-line treatment. HDDT-esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily)-will be used for 14 days.

    Drug: clarithromycin-resistant(first-line)

  • Active comparator
    empirical therapy group first-line

    The empirical therapy group will receive Bismuth-containing quadruple therapy(BQT) as first-line treatment, The BQT regime is comprising of esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days.

    Drug: empirical therapy group first-line

  • Experimental
    levofloxacin-sensitive(rescue treatment)

    If H. pylori was levofloxacin-sensitive, we will use the levofloxacin quadruple regimen as rescue treatment-esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily)-for 14 days.

    Drug: levofloxacin-sensitive(rescue treatment)

  • Experimental
    levofloxacin-resistant(rescue treatment)

    If H. pylori was levofloxacin-resistant, we will use furazolidone quadruple regimen as rescue treatment-esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily)-for 14 days.

    Drug: levofloxacin-resistant(rescue treatment)

  • Active comparator
    empirical therapy group rescue treatment

    If BQT fails, HDDT-esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily)-will be used as a rescue treatment for 14 days.

    Drug: empirical therapy group rescue treatment

Interventions

  • Drugclarithromycin-sensitive(first-line)

    esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days

    Also known as: clarithromycin triple therapy

  • Drugclarithromycin-resistant(first-line)

    esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days

    Also known as: High-dose PPI-amoxicillin dual therapy

  • Drugempirical therapy group first-line

    esomeprazole (20 mg, twice daily), colloidal bismuth pectin (150 mg, four times daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days

    Also known as: Bismuth-containing quadruple therapy

  • Druglevofloxacin-sensitive(rescue treatment)

    esomeprazole (20 mg, twice daily), levofloxacin (500 mg, once daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days

    Also known as: levofloxacin quadruple regimen

  • Druglevofloxacin-resistant(rescue treatment)

    esomeprazole (20 mg, twice daily), furazolidone (100 mg, twice daily), amoxicillin (1.0 g, twice daily), and colloidal bismuth pectin (150 mg, four times daily) for 14 days

    Also known as: furazolidone quadruple regimen

  • Drugempirical therapy group rescue treatment

    esomeprazole (20 mg, four times daily) and amoxicillin (750 mg, four times daily) for 14 days

    Also known as: High-dose PPI-amoxicillin dual therapy

06

What researchers measure

Primary outcomes

  1. the first-line H. pylori eradication rate

    the proportion of participants with successful H. pylori eradication, as determined by 13C-Urea breath test(UBT), at least 4 weeks after the end of the first-line treatment period between Susceptibility-guided therapy(SGT) and empirical therapy(ET) group.

    Time frame: 4-8 weeks after the end of treatment.

Secondary outcomes

  1. the rescue H. pylori eradication rate

    The second line eradication rate between SGT and ET group.

    Time frame: 4-8 weeks after the second treatment

  2. the overall H.pylori eradication rate

    the total H.pylori eradication rate (first-line and second-line)between SGT and ET group.

    Time frame: 4-8 weeks after the second treatment

  3. high-dose dual therapy eradication rate

    compare H. pylori eradication rate between clarithromycin resistance group and empirical BQT failure group.

    Time frame: 4-8 weeks after the second treatment

  4. Adverse events and compliance

    3 days after the completion of therapy according to a data collection form

    Time frame: 3 days after the end of treatment.

07

Study locations

1 of 1 sites recruiting
  • Liaocheng people's hospital
    Liaocheng, Shandong 252000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Feb 2024, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2022
First posted
Sep 22, 2022
StartActual
Sep 20, 2022
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2024
Last update
Dec 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05549115
Lead sponsor
Liaocheng People's Hospital
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Sep 20, 2022
Primary completion
Feb 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
Dec 12, 2023

Study contacts

Jing run Zhao, Dr
Contact
zhjrun77@163.com
+86-635-8276373
Jing run Zhao, Dr
study chair · Liaocheng People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion